Furthermore, reduced objective response rates following neoadjuvant treatment in individuals with metabolic syndrome-related breast cancer are linked to elevated serum levels of adipocytokines and IL-18bp (binding proteins to IL-18 and inhibiting its function).181. The gene discussed is IL18; the disease is breast carcinoma.